Filing Details
- Accession Number:
- 0001567619-21-018722
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-26 16:35:03
- Reporting Period:
- 2021-10-22
- Accepted Time:
- 2021-10-26 16:35:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1634379 | Metacrine Inc. | MTCR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1329161 | J Robert Adelman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1504130 | Venbio Global Strategic Fund, L.p. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1770834 | Venbio Global Strategic Gp, L.p. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No | |
| 1770835 | Venbio Global Strategic Gp, Ltd. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-10-22 | 75,035 | $1.64 | 2,984,088 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-25 | 540,667 | $1.49 | 2,443,421 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman (collectively, the "Directors") are each a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., and the Directors disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.66, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.59, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Billionaire Hedge Funds
